NFE2L2 and ovarian carcinoma: Conversely, the combined therapeutics of trastuzumab and pertuzumab promoted DNA methylation on the Nfe2l2 promoter in human ovarian cancer cells, weakening the expression of Nrf2 and attenuating its antioxidant capacity, thereby achieving an anticancer effect 59.